You just read:

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

News provided by

Intrexon Corporation , ActoBio Therapeutics, Inc.

Mar 29, 2018, 09:26 ET